Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | ROS1 | P08922 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19187758 | 0.87 | CYP11B1 (0.60) | CYP11B1CYP11B2MMP12PDE3BPDE3A | |
| SCHEMBL436631 | 0.86 | MMP12 (0.51) | CYP11B1CYP11B2MMP12HTR5AEPHX2 | |
| SCHEMBL30695802 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL3068531 | 0.79 | AHR (0.56) | CYP11B1CYP11B2HTR5APDE3BPDE3A | |
| SCHEMBL31261247 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2HTR5APDE3BPDE3A | |
| SCHEMBL3597262 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2MMP12PDE3BPDE3A | |
| SCHEMBL13692913 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL10916724 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL787497 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL6907798 | 0.79 | HTR5A (0.42) | CYP11B1CYP11B2MMP12HTR5AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-1948623-A2 | HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20070265242-A1 | Novel Carbapenem Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265242-A1 | Novel Carbapenem Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1785426-A1 | NOVEL CARBAPENEM COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007041077-A2 | HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | CYP11B1 2557/4885CYP11B2 2738/4885MMP12 859/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | CYP11B1 111/4885CYP11B2 107/4885MMP12 1563/4885 |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | NR1H2, NR1H3, RXRA | CYP11B1 155/4885CYP11B2 234/4885MMP12 4696/4885 |
| US-20070265242-A1 | Novel Carbapenem Compound | C1R, C3AR1, OXA1L | CYP11B1 1490/4885CYP11B2 2182/4885MMP12 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.